PURPOSE: Chemotherapy improves the survival rate of stage III colon cancer patients. The combination of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) has emerged as the standard of care. This prospective study evaluates potential alterations in cognitive function in FOLFOX4-treated patients. METHODS: We evaluated 57 consecutive colorectal cancer patients who received adjuvant chemotherapy with FOLFOX4. Patients underwent a complete battery of neuropsychological tests at three different times: before (T0), at the end (T1), and 6 months after treatment (T2). RESULTS: We have analyzed cognitive impairment (Mini Mental State Examination, MMSE), visuo-spatial memory (Clock Drawing Test, CDT, Rey Complex Figure, copy and recall), information processing speed (Trial Making Test-A, TMT-A, and Trial Making Test-B, TMT-B), verbal memory (Rey Auditory Verbal Learning Test, call and recall), emotional distress (Psychological Distress Inventory, PDI), anxiety (State and Trait Anxiety Inventory, STAI-Y1 and Y2), and depression (Beck Depression Inventory, BDI). Then we have calculated, for each test and for each interval of time, mean ± standard deviation for the mean. In a subsequent phase, we tested the significance of different results through the ANOVA analysis for repeated measures. In this case, we could not find any statistically significant modification in cognitive function, but we could notice an improvement in emotional performance, anxiety and depression a short time after chemotherapy administration. CONCLUSIONS: We found no effect on cognitive function related to chemotherapy, the only little modification is about some emotional performance during chemotherapy. These findings may be explained by the central role of the psychological adaptation process, which occurs during the period from diagnosis to completion of treatment and is characterized by anxiety and adjustment depression. Our results seem to rule out any significant cognitive impairment due to adjuvant FOLFOX4 chemotherapy in colon cancer patients.
PURPOSE: Chemotherapy improves the survival rate of stage III colon cancerpatients. The combination of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) has emerged as the standard of care. This prospective study evaluates potential alterations in cognitive function in FOLFOX4-treated patients. METHODS: We evaluated 57 consecutive colorectal cancerpatients who received adjuvant chemotherapy with FOLFOX4. Patients underwent a complete battery of neuropsychological tests at three different times: before (T0), at the end (T1), and 6 months after treatment (T2). RESULTS: We have analyzed cognitive impairment (Mini Mental State Examination, MMSE), visuo-spatial memory (Clock Drawing Test, CDT, Rey Complex Figure, copy and recall), information processing speed (Trial Making Test-A, TMT-A, and Trial Making Test-B, TMT-B), verbal memory (Rey Auditory Verbal Learning Test, call and recall), emotional distress (Psychological Distress Inventory, PDI), anxiety (State and Trait Anxiety Inventory, STAI-Y1 and Y2), and depression (Beck Depression Inventory, BDI). Then we have calculated, for each test and for each interval of time, mean ± standard deviation for the mean. In a subsequent phase, we tested the significance of different results through the ANOVA analysis for repeated measures. In this case, we could not find any statistically significant modification in cognitive function, but we could notice an improvement in emotional performance, anxiety and depression a short time after chemotherapy administration. CONCLUSIONS: We found no effect on cognitive function related to chemotherapy, the only little modification is about some emotional performance during chemotherapy. These findings may be explained by the central role of the psychological adaptation process, which occurs during the period from diagnosis to completion of treatment and is characterized by anxiety and adjustment depression. Our results seem to rule out any significant cognitive impairment due to adjuvant FOLFOX4 chemotherapy in colon cancerpatients.
Authors: Sadhna Kohli; Jennifer J Griggs; Joseph A Roscoe; Pascal Jean-Pierre; Christopher Bole; Karen M Mustian; Renae Hill; Kelly Smith; Howard Gross; Gary R Morrow Journal: J Oncol Pract Date: 2007-03 Impact factor: 3.840
Authors: Tim A Ahles; Andrew J Saykin; Brenna C McDonald; Yuelin Li; Charlotte T Furstenberg; Brett S Hanscom; Tamsin J Mulrooney; Gary N Schwartz; Peter A Kaufman Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Bruce A Cooper; Judy Mastick; Melissa Mazor; Melisa Wong; Steven M Paul; Yvette P Conley; Thierry Jahan; Christine Ritchie; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2018-08-22 Impact factor: 2.398
Authors: J Vardy; H M Dhillon; G R Pond; S B Rourke; W Xu; A Dodd; C Renton; A Park; T Bekele; J Ringash; H Zhang; R Burkes; S J Clarke; I F Tannock Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: Janette L Vardy; Haryana M Dhillon; Gregory R Pond; Sean B Rourke; Tsegaye Bekele; Corrinne Renton; Anna Dodd; Haibo Zhang; Philip Beale; Stephen Clarke; Ian F Tannock Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Juan Antonio Cruzado; Sonia López-Santiago; Virginia Martínez-Marín; Gema José-Moreno; Ana Belén Custodio; Jaime Feliu Journal: Support Care Cancer Date: 2014-02-18 Impact factor: 3.603
Authors: Moira A Visovatti; Patricia A Reuter-Lorenz; Alfred E Chang; Laurel Northouse; Bernadine Cimprich Journal: Oncol Nurs Forum Date: 2016-03 Impact factor: 1.803
Authors: Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa Journal: Arch Toxicol Date: 2021-11-02 Impact factor: 5.153